Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • fh_fingolfin
    Junior Member
    • Nov 2012
    • 6

    #1

    Bioinformatician in Cancer Biology

    The Research Institute of Molecular Pathology (IMP) and the Medical University of Vienna (MUW) in Vienna, Austria, are recruiting a highly motivated and well-organized bioinformatician for a collaborative translational research project focused on investigating the molecular basis of cancer and discovering new targets for innovative therapeutic approaches.

    The successful candidate will contribute to experimental design, perform method development, and integrative data analysis on large (epi)genomic datasets produced by cutting-edge sequencing technologies (e.g. SLAMseq(1), single cell sequencing) and standard sequencing approaches (whole genome sequencing, exome sequencing, RNA-seq and ChIP-seq) from patient samples and experimental model systems.
    The candidate will work closely with a dynamic and ambitious group of cancer biologists led by Anna Obenauf and Johannes Zuber (IMP), and physician-scientists led by Thomas Wiesner (MUW).

    Successful candidates should:
    1. have profound experience in NGS data analysis and deep knowledge of standard tools and data formats.
    2. have a sound knowledge of statistics.
    3. have excellent knowledge of at least one scripting language and hands-on expertise with R/Bioconductor.
    4. have experience with mining and integrative analysis of large data.
    5. have excellent communication skills in English, an ability to translate and communicate results, and a basic understanding of cancer biology.
    6. hold an academic degree such as a BSc, MSc, PhD in Bioinformatics, Biostatistics, or Life Sciences.

    As bioinformatician in our team you will:
    1. interpret and integrate comprehensive sequencing datasets (variant calling from whole genome and exome sequencing, RNAseq, ChIPseq), generated by our team with support from our NGS facility (with access to all state-of-the-art sequencing platforms (Illumina, PacBio, Nanopore) and single cell sequencing http://www.vbcf.ac.at/facilities/nex...on-sequencing/).
    2. develop methods for cutting-edge technologies (e.g. SLAMdunk (2) and design and analyze complex libraries for large scale CRISPR screens (3).
    3. be in charge of data mining from publicly available datasets (e.g. TCGA, ICGC, datasets on GEO) to identify gene signatures of disease progression, features of the tumor microenvironment etc., to formulate hypotheses which will then be tested in our experimental systems (4,5).
    4. become an integral member of our cancer biology team with deep intellectual project involvement and close interactions with wet lab scientists and physician scientists.
    5. be embedded in a group of experienced computational biologists/bioinformaticians with complementary expertise affiliated with different research groups at the IMP and the MUW, ensuring constant interactions, support, and training.
    The salary is commensurate with qualifications/experience and includes a comprehensive benefits package.

    Applications, including a letter of motivation describing your particular interest in this position and past research experiences, a CV, GitHub account if available, and the names and contact details of referees should be sent to [email protected]. The application deadline is May 25th, 2018.

    Further information:

    https://t.co/vgxKeXCdhF

    What are the molecular mechanisms behind cancer? How can we exploit the vulnerabilities of cancer cells to find opportunities for new therapies? Molecular mechanisms of metastasis and drug resistance research at the Institute of Molecular Pathology (IMP).


    Why are cancer cells immortal, what genes do they depend on, and how can we exploit cancer-specific vulnerabilities for cancer therapy? Finding and probing cancer drug targets using advanced RNAi technologies research at the Institute of Molecular Pathology (IMP).


    (1) Muhar M, et al., Science, 2018, (2) http://t-neumann.github.io/slamdunk/,(3) Rathert P, et al. Nature, 2015, (4) Obenauf AC et al., Nature, 2015, (5) Wiesner T et al., Nature, 2015

Latest Articles

Collapse

  • SEQadmin2
    16S/ITS Profiling vs. Shotgun Metagenomics: What Changes in Your Workflow?
    by SEQadmin2




    NGS has revolutionized clinical microbiology by offering new ways to identify and surveil pathogens without prior knowledge of the target. One popular approach is 16S rRNA and ITS amplicon sequencing, which targets specific microbial markers. But studies are increasingly incorporating shotgun metagenomics, a technique that sequences all DNA from a sample without targeting specific microbial markers. This approach allows more detailed taxonomic classification, detection...
    10-30-2026, 06:46 AM
  • SEQadmin2
    Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
    by SEQadmin2



    Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

    Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
    ...
    10-14-2026, 09:55 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, 10-28-2026, 09:57 AM
0 responses
31 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-28-2026, 09:51 AM
0 responses
21 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-22-2026, 11:13 AM
0 responses
71 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-22-2026, 10:48 AM
0 responses
48 views
0 reactions
Last Post SEQadmin2  
Working...